MAIA Biotechnology Announces $2.25 Million Private Placement

Core Viewpoint - MAIA Biotechnology, Inc. has announced a private placement of 1,733,766 shares of common stock at a price of $1.30 per share, along with warrants for additional shares, aiming to raise approximately $2.25 million to fund clinical trials and working capital [1][2]. Group 1: Private Placement Details - The private placement involves the sale of 1,733,766 shares at $1.30 each, with each share accompanied by a warrant to purchase one additional share at an exercise price of $1.57 [1]. - The warrants are exercisable six months after issuance and have a term of three years [1]. - The expected gross proceeds from the offering are approximately $2.25 million, prior to offering expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund Step 1 of Part C of the Phase II trial THIO-101 and for general working capital [2]. Group 3: Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [5].